Antonio Mafrici

Antonio Mafrici

Auto-generated profile, based on publicly available information

Antonio Mafrici

Cardiology Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, 20142 Milan, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2021 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
ACAlberto Cereda
Alberto Cereda
CCCristina Conca
Cristina Conca
LBLucia Barbieri
Lucia Barbieri
GFGiulia Ferrante
Giulia Ferrante
GTGabriele Tumminello
Gabriele Tumminello
AMAntonio Mafrici
Antonio Mafrici

1 November 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
ARAlberto Roghi
Alberto Roghi
EPErika Poggiali
Erika Poggiali
LDLorena Duca
Lorena Duca
AMAntonio Mafrici
Antonio Mafrici
PPPatrizia Pedrotti
Patrizia Pedrotti
MCMaria Domenica Cappellini
Maria Domenica Cappellini

Verified
Journal Article
Open access
PDF file
GTGabriele Tumminello
Gabriele Tumminello
ACAlberto Cereda
Alberto Cereda
LBLucia Barbieri
Lucia Barbieri
Giuseppe Biondi-ZoccaiGiuseppe Biondi-Zoccai
Giuseppe Biondi-Zoccai
SLStefano Lucreziotti
Stefano Lucreziotti
Stefano CarugoStefano Carugo
Stefano Carugo
The treatment of acute myocardial infarction is early revascularization. Heart failure and cardiogenic shock may complicate acute myocardial infarction despite applying the best available strategy. Levosimendan is a relatively new drug to treat heart failure with a peculiar mechanism of action: calcium sensitization of myocardial fibres. Levosimendan has a direct inotropic effect but also pleiotropic effects; through the K+ATP channel’s opening, it also has a vasodilator effect which may participate concretely in the global effects of the drug. The focus of the literature is on the anti-heart failure and anti-cardiogenic shock properties of Levosimendan, but it may have effects also preventing the development of myocardial insufficiency in acute myocardial infarction. The aim of the meta-analysis is to evaluate the effect of Levosimendan on acute myocardial infarction in placebo-controlled trials. Based on the eight studies selected, we found a beneficial effect of Levosimendan on acute and long-term mortality of patients affected by acute myocardial infarction. With caution in interpreting the results of this meta-analysis, our data support the idea that Levosimendan may already have a role in the treatment of acute ischemic heart disease. Further studies specifically designed to investigate the early role in the treatment of ischemic heart failure are needed.

1 October 2020 in IJC Heart & Vasculature
Verified
Journal Article
Open access
GTGabriele Tumminello
Gabriele Tumminello
LBLucia Barbieri
Lucia Barbieri
SLStefano Lucreziotti
Stefano Lucreziotti
DGDomitilla Gentile
Domitilla Gentile
BCBarbara Conconi
Barbara Conconi
Stefano CarugoStefano Carugo
Stefano Carugo
On March 11th 2020 the World Health Organization declared the pandemic infection of SARS-CoV-2 (COVID-19) and Italy was one of the most affected country. The regional Emergency Medical System (EMS) founded itself facing an exponential increase in hospitalizations with a consequent organizational system crisis. Experts from Cina, UK and US suggested to reconsider thrombolysis as the best treatment in term of balance between time consumption and operators safety for ST-segment elevation myocardial infarction (STEMI) patients respect to primary PCI (pPCI). The system reorganization consisted in a centralization of all the emergency nets: from 55 hospitals with cardiac catheterization laboratories distributed within our region offering a 24/7 service we passed to 13 Hub and 42 Spoke centres. Dedicated in-hospital paths for patients COVID positive or suspected (pCOV+) and COVID negative (pCOV−) were instituted. We analysed all consecutive patients undergoing emergency coronary angiogram from March 14 to April 14, 2020 at San Carlo Hospital in Milan comparing the two different in-hospital paths. We collected 30 STEMI patients. Eighteen patients (60%) were treated in pCOV−, while twelve patients (40%) in pCOV+. No significant differences were found among the two groups regarding key time points of STEMI care and interestingly we didn't find any treatment delay in pCOV+. In conclusion, a focused overhaul of the EMS may allow to maintain pPCI as the treatment of choice for patients and operators.

1 December 2020 in Italian Journal of Emergency Medicine
Verified
Journal Article
Open access
SLStefano Lucreziotti
Stefano Lucreziotti
MCMarco Centola
Marco Centola
LBLucia Barbieri
Lucia Barbieri
GTGabriele Tumminello
Gabriele Tumminello
BCBarbara Conconi
Barbara Conconi
Stefano CarugoStefano Carugo
Stefano Carugo